Annamarie Paulsen
Child & Adolescent Psychiatry · Conyers, GANPI 1285766055
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Otsuka America Pharmaceutical, Inc. accounts for 63.4% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2019 at $15,699 and has fallen 87.4% since, to $1,970 in 2025. Among child & adolescent psychiatry clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 605 payments — averaging $41.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$16K
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Neurocrine Biosciences, Inc.$931
- Supernus Pharmaceuticals, Inc.$892
- Teva Pharmaceuticals USA, Inc.$599
- plus $4K from 25 others
What the payments were for
- Speaking & faculty fees$11,57646%
- Travel & lodging$3,07712%
- Food & beverage$10,10440%
- Education$3501%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 76 | $15,908 |
| AbbVie(2 entities) | 98 | $1,184 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 63 | $1,121 |
| Neurocrine Biosciences, Inc. | 40 | $931 |
| Supernus Pharmaceuticals, Inc. | 46 | $892 |
| Teva Pharmaceuticals USA, Inc. | 25 | $599 |
| Takeda Pharmaceuticals U.S.A., Inc. | 49 | $596 |
| Tris Pharma Inc | 29 | $568 |
| Lundbeck LLC | 28 | $543 |
| Axsome Therapeutics, Inc. | 10 | $341 |
| Corium, LLC | 31 | $328 |
| Johnson & Johnson | 16 | $292 |
| Vanda Pharmaceuticals Inc. | 10 | $257 |
| Ironshore Pharmaceuticals Inc. | 11 | $226 |
| Jazz Pharmaceuticals Inc. | 6 | $194 |
| Bausch Health US, LLC | 11 | $189 |
| Noven Therapeutics, LLC | 9 | $169 |
| Alkermes, Inc. | 9 | $146 |
| Idorsia Pharmaceuticals US Inc | 6 | $119 |
| Collegium Pharmaceutical, Inc. | 4 | $77 |
| Indivior Inc. | 3 | $63 |
| Avanir Pharmaceuticals, Inc. | 4 | $60 |
| Almatica Pharma LLC | 3 | $47 |
| E.r. Squibb & Sons, L.L.C. | 2 | $47 |
| Arbor Pharmaceuticals, Inc. | 3 | $46 |
| Adlon Therapeutics L.p. | 3 | $45 |
| Shire North American Group Inc | 3 | $39 |
| Vertical Pharmaceuticals, LLC | 2 | $30 |
| Neos Therapeutics, LP | 2 | $29 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $13 |
| Neuronetics, Inc. | 2 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,107 in reported general payments places this provider in the 95th percentile of 91 child & adolescent psychiatry providers in Georgia.
See all child & adolescent psychiatry providers in Georgia →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 22 | $145,856 |
| RexultiBrexpiprazole | 42 | $77,055 |
| VraylarCariprazine Hcl | 38 | $60,285 |
| VyvanseLisdexamfetamine Dimesylate | 34 | $12,963 |
| Lisdexamfetamine Dimesylate | 60 | $12,006 |
| Lurasidone Hcl | 24 | $9,706 |
| Aripiprazole | 62 | $6,394 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 166 | $4,728 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 46 | $4,692 |
| Duloxetine Hcl | 165 | $3,220 |
| Quetiapine Fumarate | 120 | $2,280 |
| Bupropion XlBupropion Hcl | 81 | $2,234 |
| Alprazolam | 387 | $1,756 |
| Ziprasidone Hcl | 30 | $1,684 |
| Clonazepam | 214 | $1,351 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $599 | $145,85622 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $15,908 | $77,05542 claims |
| AbbVieVraylar | $1,184 | $60,28538 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $596 | $12,96334 claims |
| Almatica Pharma LLCSertraline Hcl | $47 | $20840 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 91 child & adolescent psychiatry providers in Georgia.
Other child & adolescent psychiatry in Conyers
- Suneel KatragaddaAtlanta$460K
- Kevin WindersSavannah$225K
- Haolat BabalakinBerkeley Lake$16K
- Heerain ShahSuwanee$14K
- Olujimi AdefisanAtlanta$14K
- Deepti BhasinWarner Robins$11K
- Mhd AlkhatibAtlanta$7K
- Mary HuberAtlanta$7K
- Olufemi TaiwoFayetteville$5K
- Jocelyn BaylissAugusta$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.